Peptide dossier, updated Oct 31, 2026
PEG-MGF
Pegylated mechano growth factor, a modified form of a splice variant of insulin-like growth factor 1. Mechano growth factor (MGF) is a splice variant of insulin-like growth factor. PEG-MGF adds a polyethylene glycol group. We found no human study of it, no registered trial, and one PubMed paper that names it, a 2026 review. This page lays out what each source actually says.
See all 9 verified records for PEG-MGF on the Records page
Human studies
ClinicalTrials.gov returns no study listing PEG-MGF or pegylated mechano growth factor as of Oct 31, 2026, and we found no published human study of it.
A broader text search returns unrelated studies of IGF-1 and related drugs. Registry entries are written by sponsors and are not reviewed for scientific merit. The absence of a registered study is not evidence about safety or effect.
FDA review
FDA’s safety-risk page (content current Apr 22, 2026) is the one FDA document on PEG-MGF that we read.
What FDA’s page says
- FDA lists “Mechano Growth Factor Pegylated (PEG-MGF)” among bulk drug substances that were nominated and later withdrawn, previously in category 2 under its interim compounding policies.
- It says compounded drugs containing it may pose significant risk for immunogenicity for certain routes, and may have complexities with peptide-related impurities and API characterization.
- It says FDA has not identified any human exposure data on drug products containing PEG-MGF by any route, and lacks important information on any safety issues, including whether it would cause harm if administered to humans.
What we did not find
- We found no FDA briefing document or advisory committee evaluation for PEG-MGF. FDA’s notice for the July meeting does not name it, so the safety-risk page entry is the only FDA statement on it that we read.
- No FDA statement on the composition of products sold online.
Published research
PubMed returns 1 result for “PEG-MGF” in the title or abstract and 194 for “mechano growth factor.” The papers we read on MGF are laboratory work and studies of how to detect it in doping control.
What the papers show
- Review, 2026. Lists PEG-MGF among IGF-1 analogues marketed as “research compounds.” It reports adverse effects for the class of peptides it covers, including endocrine and metabolic disturbances, fluid retention, muscle and joint symptoms and injection-site reactions, and notes the uncertainty about composition and dose in unregulated supply. The effects are reported for the group, not PEG-MGF specifically. Front Endocrinol PubMed
- Black-market product, 2012. Mass spectrometry of two black-market preparations sold as MGF found both were C-terminal amidated analogues of human MGF. The authors say MGF has not been approved for therapeutic use. Rapid Commun Mass Spectrom PubMed
- Confiscated vials, 2017. A detection and plasma-metabolism study of a variant, MGF R23H, found in confiscated vials. Drug Test Anal PubMed
Read with care
- None of these papers tests PEG-MGF in people.
- The two detection studies concern MGF analogues found in black-market products. They are not studies of PEG-MGF.
- We read abstracts only, not full text, funding or author disclosures.
FDA warning letters
We found one FDA warning letter that names PEG-MGF. It is addressed to a compounding pharmacy and is not a finding about PEG-MGF’s safety. This rests on web searches, not a full pull of FDA’s database.
| Recipient | Date | Letter | What it says |
|---|---|---|---|
| Tailor Made Compounding LLC, a compounding pharmacy | Apr 1, 2020 | Warning letter 594743 | FDA says an inspection found the firm compounding with a list of 22 bulk substances that includes PEG-MGF, and that drugs made from them were not eligible for the section 503A exemptions. The letter says none of them is covered by a USP or NF monograph or is a component of an FDA-approved drug, and that the listed substances “have not been nominated” for the bulks list. We read the letter text. |
A warning letter is FDA’s statement about one firm’s conduct on one date. It is not a finding about the substance. FDA’s list of letters cannot be searched by peptide, so other letters could exist that we did not find.
SEC filings
We found one SEC filing that names PEG-MGF. EDGAR’s full-text search was not available to us, so this rests on web searches of sec.gov.
| Filer | Filing | What it says |
|---|---|---|
| BioScience Health Innovations Inc. | Form 10-Q Filed May 11, 2026 | Lists “PEG-MGF — Muscle repair” among 14 peptides it expects to return to Category 1, following a Feb 27, 2026 statement by the HHS Secretary on a podcast. It adds that reclassification would not be FDA approval and that formal rulemaking had not been published as of April 2026. |
What a company says in a filing is its own claim about its business. It is not a finding about PEG-MGF. FDA’s page lists it as a safety risk and HHS’s Oct 30 draft policy does not cover it, per the summaries we read. We read the passage naming PEG-MGF, not the whole document.
Timeline
Newest first. Every entry links to the document it comes from.
- Government or registry record
- Journal
- Oct 30, 2026RegulatoryHHS publishes draft policy pausing enforcement on six peptides; PEG-MGF is not one of them
Per two law-firm summaries the six are BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c. The policy is a draft and not FDA approval. We could not open the policy attachment, so this rests on the summaries.
- July 23–24, 2026RegulatoryFDA advisory committee meets on seven peptides; PEG-MGF is not among them
The committee recommended six of the seven, all nonbinding. FDA’s notice of the meeting does not list PEG-MGF.
- Apr 22, 2026RegulatoryFDA’s safety-risk page lists PEG-MGF
FDA says it may pose significant immunogenicity risk and that it has found no human exposure data by any route.
- Jan 1, 2026Anti-dopingWADA’s 2026 Prohibited List names mechano growth factors (MGFs) in section S2
The 2022 list also names them. Neither names PEG-MGF specifically. We checked the 2022 and 2026 lists only.
- Apr 1, 2020EnforcementFDA warning letter to a compounding pharmacy names PEG-MGF among 22 substances
The letter says drugs the firm compounded from these bulk substances were not eligible for the 503A exemptions.
- 2017LiteratureDetection and metabolism study of a variant of MGF found in confiscated vials
Published in Drug Test Anal.
- 2012LiteratureMass spectrometry identifies amidated MGF analogues in black-market products
Published in Rapid Commun Mass Spectrom.
Still not covered
Left off rather than guessed:
- Policy coverage: HHS’s list of covered peptides sits in a policy attachment we could not open. That PEG-MGF is outside it comes from two law-firm summaries, not from the document itself.
- FDA review: We found no FDA briefing document or advisory committee evaluation for PEG-MGF. FDA’s notice for the July meeting does not name it, so the safety-risk page entry is the only FDA statement on it that we read.
- Patents: not researched for this dossier.
- Seller claims and independent lab reports: how it is marketed versus what testing finds. We have not collected testing data.
- Pegylated forms under WADA: the lists name MGFs as a class. We did not find WADA text on PEG-MGF.
- Unread items: full text of every paper; WADA lists for years other than 2022 and 2026; EU and other non-US trial registries.
- Warning letter and SEC completeness: web searches only.